Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant

Summary

This study is a Phase 2 multicenter study with a Safety Lead-in evaluating safety and efficacy of MT-401 administration to patients with AML, who have received their first allogeneic HSCT. The dose administered is 50 x 10\^6 cells (flat dosing).

Timeline

Start

2020-10-14

Primary completion

2024-03-01

Completion

2024-03-01

Outcome

Outcome not reported

Stopped (Enrollment): “Despite a plan to enroll \~195-210 participants, the ARTEMIS study was closed due to the long vein-to-vein manufacturing timeline of MT-401 after 38 participants received the autologous MT-401.”

Drugs

Indications